Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
Conditions
- Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
- BIOLOGICAL: mRNA-2752
- BIOLOGICAL: Durvalumab
Sponsor
ModernaTX, Inc.
Collaborators